
    
      Demographics, baseline disease information, prior disease-directed therapy including
      fluorouracil or capecitabine, and details of the fluorouracil or capecitabine overexposure
      (dose, cause, and timing) will be collected. Adverse events information will be collected and
      recorded. Patients will be followed for 30 days unless the patient expires or resumes
      chemotherapy within the 30 day period.
    
  